NeuroBo Pharmaceuticals Analyst Ratings
NeuroBo Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/07/2022 | 322.54% | Ladenburg Thalmann | → $6 | Initiates Coverage On | → Buy |
| 02/01/2021 | 1026.76% | HC Wainwright & Co. | $20 → $16 | Maintains | Buy |
| 06/15/2020 | 1308.45% | HC Wainwright & Co. | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 12/07/2022 | 322.54% | 拉登堡·塔爾曼 | → $6 | 開始承保 | →購買 |
| 02/01/2021 | 1026.76% | HC Wainwright公司 | $20 → $16 | 維護 | 買 |
| 06/15/2020 | 1308.45% | HC Wainwright公司 | → $20 | 開始承保 | →購買 |
What is the target price for NeuroBo Pharmaceuticals (NRBO)?
NeuroBo製藥公司(NRBO)的目標價是多少？
The latest price target for NeuroBo Pharmaceuticals (NASDAQ: NRBO) was reported by Ladenburg Thalmann on December 7, 2022. The analyst firm set a price target for $6.00 expecting NRBO to rise to within 12 months (a possible 322.54% upside). 1 analyst firms have reported ratings in the last year.
拉登堡·塔爾曼於2022年12月7日報道了NeuroBo製藥公司(納斯達克代碼：NRBO)的最新目標價。這家分析公司將目標價定為6美元，預計NRBO將在12個月內升至(可能上漲322.54%)。1家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for NeuroBo Pharmaceuticals (NRBO)?
分析師對NeuroBo製藥(NRBO)的最新評級是多少？
The latest analyst rating for NeuroBo Pharmaceuticals (NASDAQ: NRBO) was provided by Ladenburg Thalmann, and NeuroBo Pharmaceuticals initiated their buy rating.
分析師對NeuroBo製藥公司(納斯達克代碼：NRBO)的最新評級是由拉登堡·塔爾曼提供的，NeuroBo製藥公司啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for NeuroBo Pharmaceuticals (NRBO)?
NeuroBo PharmPharmticals(NRBO)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuroBo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuroBo Pharmaceuticals was filed on December 7, 2022 so you should expect the next rating to be made available sometime around December 7, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與NeuroBo製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。NeuroBo製藥的上一次評級是在2022年12月7日提交的，所以你應該預計下一次評級將在2023年12月7日左右的某個時候公佈。
Is the Analyst Rating NeuroBo Pharmaceuticals (NRBO) correct?
分析師對NeuroBo製藥公司(NRBO)的評級正確嗎？
While ratings are subjective and will change, the latest NeuroBo Pharmaceuticals (NRBO) rating was a initiated with a price target of $0.00 to $6.00. The current price NeuroBo Pharmaceuticals (NRBO) is trading at is $1.42, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的NeuroBo製藥(NRBO)評級是以0.00美元至6.00美元的目標價啟動的。NeuroBo製藥公司(NRBO)目前的交易價格為1.42美元，在分析師的預測範圍內。